European Regulators Reject Omeros Marketing Authorization for Narsoplimab

Key Facts

1The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab.

The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab. Investing.com reported that the rejection concerns the treatment intended for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The regulatory body's decision follows an assessment of the data submitted by the company regarding the drug's efficacy and safety profile.

OMER closed at $18.79 on October 15, 2026, prior to the announcement of the regulatory rejection. During that session, the stock reached a high of $19.08 and a low of $18.30. This regulatory setback is significant for the biotech firm, as it impacts future revenue projections and clinical timelines for its primary drug candidate.